Last reviewed · How we verify

Saline Nonopioid anesthesia

University of Alexandria · FDA-approved active Small molecule Quality 5/100

Saline nonopioid anesthesia uses isotonic saline solution as a carrier or adjunct to deliver nonopioid anesthetic agents, avoiding opioid-related side effects.

Saline Nonopioid anesthesia, marketed by the University of Alexandria, is a unique anesthetic solution currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.

At a glance

Generic nameSaline Nonopioid anesthesia
SponsorUniversity of Alexandria
Drug classNonopioid anesthetic
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

This approach combines saline (physiologic sodium chloride solution) with nonopioid anesthetic compounds to induce and maintain anesthesia without relying on opioid medications. By eliminating opioids, the formulation aims to reduce respiratory depression, constipation, and addiction potential while maintaining adequate anesthetic depth through alternative mechanisms such as local anesthetics, sedatives, or other nonopioid agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: